After netting $200M, Synthego to break ground on its manufacturing facility

Tyler Patchen

News Reporter

California-based biotech Synthego has been mainly focused on developing CRISPR-based tools to help researchers in academia and biotech, but its latest move now is turning …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After netting $200M, Synthego to break ground on its manufacturing facility

Tyler Patchen

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

The election is Tuesday. What’s at stake for the pharma industry?

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

Is there room for MASH drugs in a GLP-1 world?

Viking's oral weight loss drug appears to have strong effect in Phase 1 trial

FDA cites Mark Cuban's drug compounding center in Dallas with sterility, quality concerns

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Af­ter net­ting $200M, Syn­thego to break ground on its man­u­fac­tur­ing fa­cil­i­ty

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

After netting $200M, Synthego to break ground on its manufacturing facility